awmsg logo



aflibercept (Eylea®)


Reference No. 1586

Publication date:
14/03/2017


Appraisal information

aflibercept (Eylea®) 40 mg/ml intravitreal injection


Company: Bayer Healthcare Pharmaceuticals
BNF category: Eye
NMG meeting date: 11/01/2017
AWMSG meeting date: 15/02/2017
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0117
Ministerial ratification: 14/03/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aflibercept (Eylea®) is recommended as an option for use within NHS Wales for the treatment of adult patients with visual impairment due to myopic choroidal neovascularisation. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download